Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 2 × Congenital Abnormalities × Vorinostat × Clear all
NCT01789255 2018-07-24

Vorinostat, Tacrolimus, and Methotrexate in Preventing GVHD After Stem Cell Transplant in Patients With Hematological Malignancies

National Cancer Institute (NCI)

Phase 2 Completed
12 enrolled 11 charts
Classical hematologyLymphoidMyeloidOther hematologic neoplasm

Chromosome 5q Deletion Syndrome, Congenital Abnormalities, Anemia, Refractory, Anemia, Refractory, with Excess of Blasts, Burkitt Lymphoma, Graft vs Host Disease, Hodgkin Disease, Leukemia, Hairy Cell, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Myeloproliferative Disorders, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Lymphoma, Large-Cell, Immunoblastic, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Intraocular Lymphoma

NCT00818649 2017-12-28

Bortezomib and Vorinostat in Treating Patients With High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia

Masonic Cancer Center, University of Minnesota

Phase 2 Terminated
16 enrolled 7 charts
Classical hematologyMyeloidOther hematologic neoplasm

Congenital Abnormalities, Anemia, Refractory, with Excess of Blasts, Leukemia, Erythroblastic, Acute, Leukemia, Leukemia, Megakaryoblastic, Acute, Leukemia, Monocytic, Acute, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Acute